Capital Group Dividend Value ETF Gains from Eli Lilly's Trial Success, 6.06% Weight
Selpercatinib showed a statistically significant reduction in recurrence or death risk in 151 early-stage non-small cell lung cancer patients in the Phase 3 LIBRETTO-432 trial. The Capital Group Dividend Value ETF’s 6.06% Eli Lilly holding could benefit from the drug’s positive event-free survival outcomes.
1. Phase 3 Trial Demonstrates Significant Survival Benefit
The LIBRETTO-432 trial enrolled 151 patients with early-stage non-small cell lung cancer and showed a highly statistically significant improvement in event-free survival for those receiving selpercatinib versus placebo. The safety profile remained consistent with previous studies, reinforcing the value of selective RET kinase inhibition as adjuvant therapy in RET fusion-positive cases.
2. Implications for ETF Performance
With a 6.06% allocation to Eli Lilly, the Capital Group Dividend Value ETF stands to gain from potential share appreciation driven by these trial results. Eli Lilly shares have rallied 21.33% over the past 12 months, trading above key support and nearing 52-week highs, suggesting that positive clinical developments could further bolster the ETF’s returns.